Thrombotic disorderVenous Thromboembolism: A Public Health Concern
Introduction
Venous thromboembolism (VTE) is a condition in which the blood clots inappropriately, causing considerable morbidity and mortality. The term VTE encompasses a continuum that includes both deep vein thrombosis (DVT), clots in the deep veins of the body; and pulmonary embolism (PE), which occurs when a clot breaks free and enters the arteries of the lungs. All races and ethnicities are affected by VTE, as are both genders and all age groups. With many of the known risk factors—advanced age, immobility, surgery, obesity—increasing in society, it is an important and growing public health problem. Yet, until recently, this condition has received little attention from the public health community. Fortunately, in many cases, VTE is preventable; thus, the importance of research and prevention of VTE is being increasingly recognized. However, critical and essential public health pieces are still missing. The current paper provides an overview of the epidemiology of VTE; discusses some recent, key public health activities; and identifies gaps in essential functions that are needed to prevent and reduce morbidity and mortality.
Section snippets
Epidemiology
Clinically, patients with VTE can be defined as presenting with DVT, PE, or both. About two thirds of patients with VTE present for care with DVT, and the remaining one third present with PE, which is the primary cause of mortality associated with VTE, often resulting in sudden death. It is also the leading cause of preventable hospital death and a leading cause of maternal mortality in the U.S. 1, 2
Public Health Activities and Gaps
Recently, there has been a marked increase in federal and national efforts to raise awareness about VTE and acknowledge it as a growing and important public health problem (Figure 1). In 2001, the Agency for Healthcare Research and Quality (AHRQ) identified prevention of VTE through appropriate thromboprophylaxis as the number-one safety practice for hospitals. 37 In 2003, the American Public Health Association (APHA) and the Centers for Disease Control and Prevention (CDC) held a Leadership
Summary and Conclusion
Venous thromboembolism is a major public health problem that affects an estimated 300,000–600,000 individuals in the U.S. each year. With many of the known acquired risks increasing in the U.S. population, we can expect to see growing numbers of people affected by VTE. Increasing surveillance, research, and awareness of VTE must be a priority. By employing a comprehensive public health approach to learning about the burden and causes of VTE and raising awareness among the public and healthcare
References (54)
- et al.
Effects of race and ethnicity on the incidence of venous thromboembolism
Thromb Res
(2009) - et al.
Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology
Am J Med
(2004) - et al.
Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop
Am J Prev Med
(2010) - et al.
The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study
J Thromb Haemost
(2003) Venous thrombosis: a multicausal disease
Lancet
(1999)Venous thromboembolism: disease burden, outcomes and risk factors
J Thromb Haemost
(2005)- et al.
Sickle cell trait and the risk of venous thromboembolism among blacks
Blood
(2007) - et al.
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
Lancet
(1994) - et al.
Venous thrombosis in the elderly: more questions than answers
Blood
(2007) - et al.
Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects
J Lab Clin Med
(1998)